Home › Research › Tau biomarkers
APOE Genotype and Fluid Biomarkers of Blood-Brain Barrier Integrity: A Systematic Review and Meta-Analysis
Lucas W, Murphy MJ, Riddell N.. medRxiv, 2026-09-29
Topic: Genetics and APOE
Plain-language summary
Apolipoprotein E (APOE) genotype is theorised to influence dementia risk partly through effects on blood–brain barrier (BBB) function, but clinical studies examining APOE effects on BBB biomarkers report inconsistent results. Therefore, this systematic review and meta-analysis quantified associations between APOE genotype and two commonly used fluid biomarkers of CNS barrier function: cerebrospinal fluid (CSF)/serum albumin quotient (Q-Alb), and soluble platelet-derived growth factor receptor beta (sPDGFRβ). Ovid MEDLINE, Embase, and Web of Science were searched on 30 th June, 2026. Eligible peer-reviewed human studies reported Q-Alb or blood or CSF sPDGFRβ by APOE genotype. Risk of bias was assessed using the Joanna Briggs Institute checklist. Twenty-eight studies involving 5,375 participants were included: 17 assessed Q-Alb and 11 assessed sPDGFRβ. Random-effects meta-analyses determined that APOE ε2 carriage was associated with higher Q-Alb ( g = 0.29, 95% CI 0.11 to 0.46). APOE ε4 carriage was not associated with Q-Alb overall ( g = .13, 95% CI -.17 to .43) or sPDGFRβ overall ( g = .10, 95% CI -.21 to .40). Genotype-specific Q-Alb analyses suggested medium positive but non-significant effects among ε4/ε4 and ε2/ε4 carrier subgroups. For sPDGFRβ, exploratory subgroup analysis revealed effect estimates near zero in cognitively unimpaired participants, and a small positive non-significant effect in cognitively impaired participants. Larger effects were also observed in samples with an older mean age, although this was not statistically significant. Overall, evidence for APOE ε4-associated alterations in Q-Alb and sPDGFRβ remained inconclusive, highlighting the need for further study across the spectrum of cognitive ageing and dementia. In contrast, APOE ε2 carriage was associated with greater barrier dysfunction as indexed by Q-Alb, broadening the predominant focus on APOE ε4 and identifying ε2 as a potentially important but understudied contributor to altered neurovascular function.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lucas, W., Murphy, M. J., & Riddell, N. (2026). APOE Genotype and Fluid Biomarkers of Blood-Brain Barrier Integrity: A Systematic Review and Meta-Analysis. medRxiv. https://doi.org/10.64898/2026.09.27.26364123
Vancouver
Lucas W, Murphy MJ, Riddell N. APOE Genotype and Fluid Biomarkers of Blood-Brain Barrier Integrity: A Systematic Review and Meta-Analysis. medRxiv. 2026. doi:10.64898/2026.09.27.26364123.
BibTeX
@article{lucas2026-9a749401,
author = {Lucas, W. and Murphy, M. J. and Riddell, N.},
title = {{APOE Genotype and Fluid Biomarkers of Blood-Brain Barrier Integrity: A Systematic Review and Meta-Analysis}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.09.27.26364123},
url = {https://doi.org/10.64898/2026.09.27.26364123}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Apolipoprotein E (APOE) genotype is theorised to influence dementia risk partly through effects on blood–brain barrier (BBB) function, but clinical studies examining APOE effects on BBB biomarkers report inconsistent results.
- Random-effects meta-analyses determined that APOE ε2 carriage was associated with higher Q-Alb ( g = 0.29, 95% CI 0.11 to 0.46).
- APOE ε4 carriage was not associated with Q-Alb overall ( g = .13, 95% CI -.17 to .43) or sPDGFRβ overall ( g = .10, 95% CI -.21 to .40).
- Genotype-specific Q-Alb analyses suggested medium positive but non-significant effects among ε4/ε4 and ε2/ε4 carrier subgroups.
- For sPDGFRβ, exploratory subgroup analysis revealed effect estimates near zero in cognitively unimpaired participants, and a small positive non-significant effect in cognitively impaired participants.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designsystematic review
- Participants5,375
- Evidence strengthHigh
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 56 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for effect reported because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 35 of the 62 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 5,375 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 35 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 35 of the 62 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “apoe2”
265 studies in the library carry the topic tag “apoe2”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.